Paper Details

  1. Home
  2. Paper Details

A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors.

Author: BowmanD, CostantinoJ, CoutureJ, DimitrovN V, FisherB, FisherE R, PoissonR, RedmondC, WickerhamD L, WolmarkN

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
Research Support, U.S. Gov't, P.H.S.Research funding provided by the Public Health Service (PHS).

Overview

Tamoxifen, an anti-estrogen drug, was studied in a randomized trial of 2644 patients with breast cancer. While tamoxifen did not improve overall survival, it significantly prolonged disease-free survival, particularly in patients under 50 years old. It reduced the rate of treatment failure at local and distant sites.
Paper Details　
Original Abstract of the Article :
We conducted a randomized, double-blind, placebo-controlled trial of postoperative therapy with tamoxifen (10 mg twice a day) in 2644 patients with breast cancer, histologically negative axillary nodes, and estrogen-receptor-positive (greater than or equal to 10 fmol) tumors. No survival advantage w...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1056/NEJM198902233200802

データ提供：米国国立医学図書館（NLM）

Tamoxifen: A Beacon of Hope for Breast Cancer Patients

Breast cancer is a challenging diagnosis, often casting a long shadow of fear and uncertainty. This research investigates the effectiveness of tamoxifen, a medication commonly used to treat breast cancer, in improving outcomes for patients with node-negative breast cancer and estrogen-receptor-positive tumors.

Tamoxifen's Protective Shield

The study's findings revealed a significant improvement in disease-free survival among patients treated with tamoxifen compared to those receiving placebo. Tamoxifen's impact was particularly pronounced in women under 50 years old, highlighting the potential for this medication to significantly reduce the risk of cancer recurrence.

Empowering Breast Cancer Patients

This research offers a beacon of hope for individuals diagnosed with breast cancer. The positive outcomes observed in the study demonstrate the potential of tamoxifen to improve treatment outcomes, empowering patients to face their diagnosis with greater confidence and optimism.

Dr.Camel's Conclusion

This study underscores the significant role of tamoxifen in the fight against breast cancer, offering a valuable tool for improving treatment outcomes and enhancing the lives of patients facing this challenging diagnosis.

Date :
  1. Date Completed 1989-03-13
  2. Date Revised 2022-03-11
Further Info :

Pubmed ID

2644532

DOI: Digital Object Identifier

10.1056/NEJM198902233200802

Related Literature

Article Analysis
・Effects of tamoxifen
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.